CytomX Therapeutics宣布任命 Charles Fuchs博士（医学博士、公共卫生硕士）为董事会成员-动脉网

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

GlobeNewswire 等信源发布 2026-07-27 11:59



可切换为仅中文







SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.

加利福尼亚州南旧金山，2026年7月27日（环球电讯社）——掩蔽型条件激活生物制剂领域的领导者CytomX Therapeutics, Inc.（纳斯达克股票代码：CTMX）今日宣布任命Charles Fuchs医学博士、公共卫生硕士为公司董事会成员。

“We are pleased to welcome Dr. Fuchs to our Board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. “Dr. Fuchs is a highly accomplished oncology expert and industry leader with more than three decades of experience across academia and global drug development, including advancing multiple cancer therapies from early research through approval.

“我们很高兴欢迎福克斯博士加入我们的董事会，”CytomX Therapeutics 的首席执行官兼董事长肖恩·麦卡锡（Sean McCarthy）博士表示。“福克斯博士是一位成就卓著的肿瘤学专家和业界领袖，在学术界和全球药物开发领域拥有三十多年的经验，包括推动多种癌症疗法从早期研究直至获批上市。”

His expertise in oncology product development and specifically in gastrointestinal oncology will be invaluable as we continue to advance Varseta-M and the broader PROBODY therapeutic pipeline to improve patient outcomes.”.

“他在肿瘤产品开发，尤其是胃肠道肿瘤领域的专业知识，将在我们持续推进 Varseta-M 及更广泛的 PROBODY 治疗管线以改善患者预后方面发挥不可或缺的作用。”

Dr. Fuchs has more than three decades of leadership experience across oncology research and biopharmaceutical drug development. Charles most recently served as Chief Medical Officer of Tubulis, where he oversees clinical strategy and pipeline development. Prior to joining Tubulis, he served as Senior Vice President and Global Head of oncology and hematology drug development at Genentech and Roche, where he led multiple novel therapies to approval, including Lunsumio, Columvi, Polivy, and Tecentriq.

福克斯博士在肿瘤学研究和生物制药药物开发领域拥有三十多年的领导经验。查尔斯最近担任图布利斯公司首席医疗官，负责监督临床战略和管线开发。在加入图布利斯之前，他在基因泰克和罗氏担任高级副总裁兼全球肿瘤学和血液学药物开发负责人，期间领导多种创新疗法获得批准，包括Lunsumio、Columvi、Polivy和Tecentriq。

Before joining the pharmaceutical industry, Dr. Fuchs served as Director of the Yale Cancer Center and Physician in Chief at Smilow Cancer Hospital, where he contributed to the launch of several biotech companies and founded EvolveImmune Therapeutics. Earlier, he held several senior roles at Dana Farber Cancer Institute, including Chief of the Gastrointestinal Cancer Division, and Harvard Medical School, where he built leading research programs in gastrointestinal cancers and cancer epidemiology.

在加入制药行业之前，福克斯博士曾担任耶鲁癌症中心主任及斯米洛癌症医院首席医师，期间他助力多家生物技术公司的创立，并创办了EvolveImmune Therapeutics公司。此前，他在丹娜—法伯癌症研究所和哈佛医学院担任多个高级职务，包括胃肠道癌症科主任，并在胃肠道癌症和癌症流行病学领域建立了领先的研究项目。

Dr. Fuchs also serves as a Senior Advisor to Frazier Life Sciences. He is a board certified medical oncologist, holding an M.D. from Harvard Medical School and an M.P.H. from the Harvard T.H. Chan School of Public Health..

福克斯博士还担任弗雷泽生命科学公司的高级顾问。他是一名获得董事会认证的肿瘤内科医生，拥有哈佛医学院的医学博士学位以及哈佛大学陈曾熙公共卫生学院的公共卫生硕士学位。

“I am delighted to join CytomX’s Board at this important time for the company,” said Dr. Fuchs. “CytomX has built its highly differentiated PROBODY platform with the potential to meaningfully expand the therapeutic window of cancer therapies and address large patient populations with high unmet need.

“在公司发展的这一重要时刻，我很高兴加入CytomX的董事会，”Fuchs博士表示。“CytomX已经建立了其高度差异化的PROBODY平台，该平台有可能显著扩大癌症疗法的治疗窗口，并满足大量未满足需求的患者群体。”

I am particularly excited to see the potential of the Varseta-M EpCAM ADC program to make an important impact for colorectal cancer patients and I look forward to working with the Board and management team to help advance this product towards pivotal studies and ultimately to regulatory approval.”.

“我特别期待看到Varseta-M EpCAM ADC项目为结直肠癌患者带来重要影响，并期待与董事会和管理团队合作，共同推动该产品进入关键性研究阶段，并最终获得监管批准。”

About CytomX Therapeutics, Inc.

关于CytomX Therapeutics公司

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY

CytomX 是一家处于临床阶段、专注于肿瘤学的生物制药公司，致力于开发新型条件性激活的掩蔽型 PROBODY。

therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers.

旨在定位于肿瘤微环境的治疗药物。通过在其PROBODY治疗平台支持下开创局部生物制剂的新型研发管线，CytomX的愿景是为癌症治疗创造更安全、更有效的疗法。CytomX强大且差异化的研发管线包含多种治疗模式的治疗候选药物，包括抗体药物偶联物（“ADC”）、细胞因子和T细胞衔接器。

CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues.

CytomX 的临床阶段管线包括 varsetatug masetecan（Varseta-M；CX-2051）和 CX-801。Varseta-M 是一种掩蔽型、条件性激活的抗体偶联药物（ADC），携带拓扑异构酶 1 抑制剂载荷，靶向上皮细胞黏附分子（EpCAM）。EpCAM 是一种高表达的肿瘤抗原，由于其在正常组织中的表达，此前一直被视为不可成药靶点。

Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY.

Varseta-M 旨在为这一高潜力靶点开启治疗窗口，并最初被开发用于治疗转移性结直肠癌。Varseta-M 是与 ImmunoGen（现为艾伯维旗下公司）合作发现的。CX-801 是一种掩蔽型干扰素 alpha-2b PROBODY。

cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna.

该细胞因子在传统上对免疫肿瘤学治疗敏感以及不敏感（冷）的肿瘤中具有广泛的潜在适用性。CX-801 最初是为治疗转移性黑色素瘤而开发的。CytomX 已与包括安进（Amgen）、再生元（Regeneron）和莫德纳（Moderna）在内的多家肿瘤学领域领导者建立了战略合作关系。

For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit .

欲了解更多关于 CytomX 的信息，以及其如何致力于将条件激活疗法打造为抗癌治疗的新标准护理方案，请访问。

www.cytomx.com

and follow us on

并在关注我们

领英

and

和

(formerly Twitter)

（前身为 Twitter）

。

Company Contact:

公司联系人：